Media Release 29 March 2023

Australian Innovators Pursue $3.6Bn Erectile Dysfunction (ED) Market Brisbane-based LTR Pharma has today secured Ethics Approval for a bio-equivalence1 clinical study of its intranasal spray for erectile dysfunction (ED), ‘SPONTAN™’ – a crucial step in fast-tracking approval for this world-first product with the U.S. Food and Drug Administration (FDA). SPONTAN’s unique delivery technology (‘Intranasal’) bypasses […]